Skip to main content

Table 1 The combined evaluation response approach

From: Quantitative mathematical objective evaluation of contrast-enhanced spectral mammogram in the assessment of response to neoadjuvant chemotherapy and prediction of residual disease in breast cancer

Type Tumor largest diameter Intensity of enhancement
• Progressive disease Increase +/− change in the intensity
• Stable disease No change in size No change
• Poor response Up to 30% decrease Decrease in intensity
• Moderate response 30–60% decrease Decrease in intensity
• Marked response > 60% decrease Residual faint enhancement
• Complete Response No residual lesion seen